Long-term, observational cohort study of adults with plaque psoriasis (PsO), who are new users of deucravacitinib, tumour necrosis factor inhibitor (TNFi) biologics, non-TNFi biologics, or non-biologic therapies in the real-world clinical setting First published 01/08/2025 Last updated 09/01/2026 EU PAS number:EUPAS1000000659 Study Planned